2026-08-10 · BOTH · TopGLP1Providers Data Desk
The brand price collapse, dated: 2023–2026
In three years, the cash price of brand GLP-1s fell from four figures a month to $299–$449 for Zepbound vials and $349 for Wegovy — a collapse driven by compounding competition, political pressure, and the manufacturers’ discovery that direct-to-consumer channels beat list-price fictions. Each cut re-priced the compounded market’s reason to exist, and the sequence explains today’s numbers better than any single price tag.
Released · Last reviewed · how we verify
2023: the four-figure era. Wegovy and Zepbound launched into US list prices in the $1,000–$1,350/month range, coverage was scarce, and the gap between list and the earliest compounded programs (then commonly $200–$400) created the largest arbitrage consumer medicine had seen in years. The compounding boom of 2023–2024 was that gap wearing a telehealth interface. 2024: the first direct channels. Lilly’s LillyDirect↗ launched with Zepbound single-dose vials for cash payers — initially $399 and $549 tiers, later $349–$499 — the first acknowledgment that a manufacturer would compete on cash price rather than cede the uninsured market. Novo followed with NovoCare↗ pricing Wegovy at $499 cash. Meanwhile the FDA declared the tirzepatide shortage resolved (October, reaffirmed December 2024), starting the legal clock on mass compounding.
2025: the squeeze from both sides. Enforcement discretion for compounded copies expired on a staggered schedule (February–May 2025 across molecules and pharmacy classes), and a federal court upheld the FDA in May — shrinking the compounded market’s legal footprint precisely as brand prices kept falling. By late 2025 the political theater around drug pricing produced concrete numbers: commitments to bring popular GLP-1 cash prices toward $245–$350 through direct channels, and on December 1, 2025, Lilly cut Zepbound vials to $299 (2.5 mg), $399 (5 mg), and $449 (7.5–15 mg) — with the maintenance rate conditional on refilling inside a 45-day window, a loyalty mechanic disguised as a price. January 5, 2026: Novo launched the oral Wegovy pill at $149–$299 and held injectable Wegovy at $349 standard with a $199 two-month intro — the first time an approved GLP-1 undercut most compounded programs outright.
What the collapse did to the comparison. Every brand cut mechanically shrank the compounded discount that justified the category. As of November 2026 the gap at maintenance is $320/month on tirzepatide (Zepbound $449 vs NexLife’s $129, read November 20, 2026) and $240/month on semaglutide (Wegovy $349 vs NexLife’s $109) — real money, but no longer a different universe, and on semaglutide arguably inside the value of FDA manufacturing oversight. The strategic reading for a buyer in 2026: brand prices have fallen on a schedule and may fall again (orforglipron and further oral competition are priced into every forecast), so long prepaid commitments to any cash program — compounded or brand — carry a new risk the 2023 market never had: the risk that the price you locked becomes the price everyone else stopped paying. The lane-by-lane comparison lives in the Zepbound analysis and the Wegovy analysis; current dated prices, always, in the database.
Historical prices reflect public announcements at the dates shown; current figures captured 2026-08-09.